Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Savient Pharmaceutical, a specialty biopharmaceutical company, has introduced the US Food and Drug Administration (FDA) approved chronic gout treatment for adult patients, Krystexxa (pegloticase) in US.
Subscribe to our email newsletter
The company claims that Krystexxa is now the first and only therapy available to address this unmet medical need.
Savient Pharma CEO John Johnson said since receiving FDA approval for Krystexxa, we have focused on preparing for a successful US launch.
"Our sales force has completed very thorough and extensive training. We are excited to deploy this highly talented and biologics experienced team into their territories," Johnson said.